Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
34 results about "Interleukin-1 Converting Enzyme" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Caspase-1/Interleukin-1 converting enzyme (ICE) is an evolutionarily conserved enzyme that proteolytically cleaves other proteins, such as the precursors of the inflammatory cytokines interleukin 1β and interleukin 18 as well as the pyroptosis inducer Gasdermin D, into active mature peptides.
Inhibitors of interleukin-1β converting enzyme
InactiveUS7288624B2Inhibit enzyme activityBiocideTripeptide ingredientsInterleukin 1β converting enzymeInterleukin 10
The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against interleukin-1 mediated diseases, including inflammatory diseases, autoimmune diseases and neurodegenerative diseases. This invention also relates to methods for inhibiting ICE activity and methods for treating interleukin-1 mediated diseases using the compounds and compositions of this invention.
Owner:VERTEX PHARMA INC
Inhibitors of interleukin-1beta converting enzyme
InactiveUS20050143436A1Inhibit enzyme activityImprove pharmacokineticsAntibacterial agentsOrganic active ingredientsInterleukin 1β converting enzymeAutoimmune condition
The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against IL-1-, apoptosis-, IGIF-, and IFN-γ-mediated diseases, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases. This invention also relates to methods for inhibiting ICE activity, for treating interleukin-1-, apoptosis-, IGIF- and IFN-γ-mediated diseases and decreasing IGIF and IFN-γ production using the compounds and compositions of this invention. This invention also relates to methods for preparing N-acylamino compounds.
Owner:VERTEX PHARMA INC
Inhibitors of interleukin-1 beta converting enzyme
InactiveUS20120165319A1Inhibit enzyme activityImprove pharmacokineticsBiocideNervous disorderInterleukin 1β converting enzymeWhite blood cell
The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against IL-1-, apoptosis-, IGIF-, and IFN-γ-mediated diseases, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases. This invention also relates to methods for inhibiting ICE activity, for treating interleukin-1-, apoptosis-, IGIF- and IFN-γ-mediated diseases and decreasing IGIF and IFN-γ production using the compounds and compositions of this invention. This invention also relates to methods for preparing N-acylamino compounds.
Owner:VERTEX PHARMA INC
Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
InactiveUS20140322158A1Organic active ingredientsNervous disorderAutoimmune conditionAutoimmune disease
A method for treating a subject afflicted with an autoimmune disease with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of administering a therapeutic amount of the pharmaceutical composition to the subject, determining whether the subject is a glatiramer acetate responder or a glatiramer acetate hypo- / non-responder by measuring the value of a biomarker selected from the group consisting of IL-10 concentration, IL-17 concentration, IL-18 concentration, TNF-α concentration, BDNF concentration, caspase-1 concentration, IL-10 / IL-18 ratio and IL-10 / IL-17 ratio in the blood of the subject, and comparing the measured value to a reference value for the biomarker to identify the subject as a glatiramer acetate responder or a glatiramer acetate hypo- / non-responder, and continuing the administration if the subject is identified as a glatiramer acetate responder, or modifying treatment of the subject if the subject is identified as a glatiramer acetate hypo- / non-responder.
Owner:TEVA PHARMA IND LTD
Chimeric pro-caspases and methods of using same
The present invention relates to a chimeric pro-caspase, which contains a pro-caspase domain and an oligomerizing domain. The invention also relates to an antibody that reacts specifically with a chimeric pro-caspase. In addition, the invention further relates to a polynucleotide encoding a chimeric pro-caspase, and to nucleotide sequences, which can hybridize specifically with a polynucleotide encoding a chimeric pro-caspase. The present invention also relates to a method of inducing apoptosis in a cell by providing a chimeric pro-caspase in the cell, wherein the chimeric pro-caspase includes a pro-caspase domain and an oligomerizing domain, whereby the chimeric pro-caspase forms an oligomer in the cell, thereby activating caspase activity of the chimeric pro-caspase and inducing apoptosis in the cell. The present invention further relates to a method of reducing the severity of a pathologic condition in a subject, by providing cells of the subject that are involved in the pathologic condition with a chimeric pro-caspase comprising a pro-caspase domain and an oligomerizing domain, whereby the chimeric pro-caspase forms an oligomer in the cells, thereby activating caspase activity of the chimeric pro-caspase, inducing apoptosis in the cells, and reducing the severity of the pathologic condition in the subject.
Owner:CALIFORNIA INST OF TECH
Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
Owner:TEVA PHARMA IND LTD
Inhibitors of interleukin-1beta converting enzyme
InactiveUS20080039449A1Inhibit enzyme activityTreatment or prophylaxis of diseasesAntibacterial agentsOrganic active ingredientsInterleukin 1β converting enzymeWhite blood cell
Owner:VERTEX PHARMA INC
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
InactiveCN102792161AEasy to understandDisease diagnosisBiological testingBCL2 ANTAGONISTCell adhesion
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more biomarkers selected from the group consisting of Tumor necrosis factor receptor superfamily member 1OB, Cadherin-16, Caspase-9, Bcl2 antagonist of cell death, Caspase-1, Cadherin-1, Poly [ADP-ribose] polymerase 1, Cyclin-dependent kinase inhibitor 1, Cadherin-5, Myoglobin, Apolipoprotein A-II, Mucin-16, Carcinoembryonic antigen-related cell adhesion molecule 5, and Cellular tumor antigen p53 as diagnostic and prognostic biomarker assays in renal injuries.
Owner:ASTUTE MEDICAL
Application of evodiamine in preparation of medicine for enhancing activation of NLRP3 inflammasomes
InactiveCN108904504APromote formationPromote pyroptosisAntibacterial agentsOrganic active ingredientsBacteroidesListeria monocytogenes
The invention discloses application of evodiamine and rutaecarpine in preparation of a medicine for enhancing the activation of NLRP3 inflammasomes. The evodiamine and the rutaecarpine can generate active Caspase-1 by enhancing activiation of macrophage inflammasomes so as to release manure inflammatory mediators such as IL-1beta and promote pyroptosis of sensitized macrophages. The activity of the evodiamine and the rutaecarpine can be used for enhancing the inflammatory response intensity of a human body and treating related diseases of insufficient activation of inflammasome including pulmonary tuberculosis and oral tuberculosis caused by intracellular infection of mycobacterium tuberculosis, diseases caused by listeria monocytogenes, related diseases caused by other intracellular infection bacteria, related diseases caused by pathogenic fungal infection, furunculosis, dental-root periapical diseases, chronic gastritis, chronic enteritis, dysentery and diarrhea and the like.
Owner:JINAN UNIVERSITY
Inhibitors of caspases
Owner:VERTEX PHARMA INC
Recombinant baculovirus vector resistant to host apoptosis
InactiveCN106636207AShorten speedDegree of reductionAntibody medical ingredientsFermentationApoptosisProtein C
The invention discloses a recombinant baculovirus vector resistant to host apoptosis, which is an antiapoptosis baculovirus expression vector realized by expressing siRNA of an insect cell caspase-1 through the vector. The baculovirus vector contains a section of special DNA sequence, the section of DNA sequence comprises a U6 promoter and an siRNA sequence of caspase-1 targeted by downstream 21nt thereof. A recombinant virus prepared by utilizing the vector can express double-strand small RNA in a host cell, caspase-1 coded by the host cell is silenced in an RNA interference way, and the apoptosis of the host cell can be further inhibited. The recombinant baculovirus vector can be used for constructing a recombinant baculovirus expressing an exogenous gene; after an insect cell is infected with the obtained recombinant baculovirus, the host apoptosis can be inhibited to remarkably enhance the heterologous protein expression level, thereby reducing the production cost.
Owner:NORTHWEST A & F UNIV
Inhibitors of interleukin 1-beta converting enzyme
InactiveUS6974809B2Inhibit enzyme activityImprove pharmacokineticsAntibacterial agentsBiocideInterleukin 1β converting enzymeDietary Alcohol
The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme (“ICE”). This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against interleukin-1-(“IL-1”), apoptosis-, interferon-γ inducing factor-(IGIF), interferon-γ-(“IFN-γ”) mediated diseases, excess dietary alcohol intake diseases, or viral diseases, including inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, and degenerative diseases. This invention also relates to methods for inhibiting ICE activity and decreasing IGIF production and IFN-γ production and methods for treating interleukin-1, apoptosis- and interferon-γ-mediated diseases using the compounds and compositions of this invention. This invention also relates to methods of preparing the compounds of this invention.
Owner:VERTEX PHARMA INC
Inhibitors of caspases
InactiveUS7358273B2Inhibit enzyme activityBiocideNervous disorderInterleukin 1β converting enzymeWhite blood cell
The present invention relates to novel classes of compounds which are caspase inhibitors, in particular interleukin-1β converting enzyme (“ICE”) inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting caspase activity and consequently, may be advantageously used as agents against interleukin-1-(“IL-1”), apoptosis-, interferon-γ inducing factor-(IGIF), or interferon-γ-(“IFN-γ”) mediated diseases, including inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, and degenerative diseases. This invention also relates to methods for inhibiting caspase activity and decreasing IGIF production and IFN-γ production and methods for treating interleukin-1, apoptosis-, and interferon-γ-mediated diseases using the compounds and compositions of this invention. This invention also relates to methods of preparing the compounds of this invention.
Owner:VERTEX PHARMA INC
Lactic acid bacteria and their cellular components inducing immunoregulatory function, and method of obtaining the same
InactiveUS20050158292A1Valid choiceAvoid problemsBiocideBacteriaCellular componentAdditive ingredient
To provide a microorganism and an ingredient thereof that contribute to prevention and treatment of immune diseases including allergy, autoimmune diseases and inflammatory bowel diseases (e.g., large-intestinal ulcer), a method of effectively selecting the microorganism, and a method of efficiently inducing immunoregulatory cells that play an important role on maintaining immunological homeostasis using the microorganism or the ingredient thereof. The present invention provides a Lactococcus and an ingredient thereof which induce production of IL-10 from mammalian dendritic or spleen cells, a method of obtaining the microorganism or the ingredient thereof by co-culturing a microorganism such as Lactococcus strains with mammalian dendritic or spleen cells to select a microbial cell having a high IL-10 production ability, a method of selecting the microorganism or the ingredient thereof by co-culturing an intestinal epithelial cell with a microorganism such as the lactic acid bacteria and selecting the cells on the basis of a caspase-1 activity and the ability of inducing the production of IL-18, and a food product or material and an animal feeding stuff or medical and pharmaceutical products which contain the lactic acid bacteria as an effective ingredient.
Owner:NAT INST OF AGROBIOLOGICAL SCI +1
Caspase-1 inhibitor targeting liver and application thereof
ActiveCN102977215AInhibition of activationActivation facilitates terminationPeptide/protein ingredientsAntipyreticAmino acid compositionPolymer
The invention discloses a caspase-1 inhibitor targeting liver. The caspase-1 inhibitor is formed by connection of human hepatitis B virus Pre-S1 peptide and caspase-1 inhibitor through a flexible connector, wherein the Pre-S1 peptide consists of amino acids from first to fiftieth of the Pre-S1 protein; and the caspase-1 inhibitor is formed by connection of trimolecular polymer of YVAD tetrapeptide and trimolecular polymer of VAD tripeptide. According to the inhibitor, the caspase-1 inhibitor is specifically targeted to a liver cell by utilizing the carrier Pre-S1 peptide which specifically targets liver, so that intrahepatic persistent chronic inflammation caused by endogenous danger signals released by injured liver cells can be blocked by terminating caspase-1 activation in the liver cell, sequential spinal cord injury of the liver cell can be blocked, body adverse response which is possibly caused by spread inhibition of caspase-1 can be reduced, and the liver cell can be specifically and effectively protected. The caspase-1 inhibitor can be used for preparing a medicament for treating intrahepatic chronic inflammation caused by endogenous danger signals released by injured liver cells.
Owner:ARMY MEDICAL UNIV
Substituted 2-amino-3-(2-amino-phenylsulfanyl)-propionic acids
The present invention relates to a new process for the preparation compounds of formula I wherein R1, R2, R3 and n are as described in the description which process comprises reacting compounds of formula II wherein R1, R2, R3, n and R4 are as described in the description, with a protease in an aqueous system containing an organic co-solvent.The compound of formula I are useful for the preparation of 1,5-benzothiazepines which are useful as enzyme inhibitors, such as protease, interleukin-1β-converting enzyme, elastase or angiotensin converting enzyme, GPCR antagonists (cholecystokinin, angiotensin II receptor).
Owner:F HOFFMANN LA ROCHE INC
Inhibitors of interleukin-1 beta converting enzyme
InactiveUS20080070953A1BiocideCarbamic acid derivatives preparationAutoimmune conditionInterleukin 1β converting enzyme
Owner:VERTEX PHARMA INC
Broad-spectrum anti-apoptosis rhabdovirus expression vector
The invention discloses a broad-spectrum anti-apoptosis rhabdovirus expression vector, and the broad-spectrum anti-apoptosis effect is achieved through the expression of the caspase-1 consensus sequence of target Spodoptera frugiperda and Trichoplusia ni insect cells by the vector. The rhabdovirus vector comprises a section of specific DNA sequence, the DNA sequence comprises the siRNA sequence ofthe consensus sequence of the target Sf-caspase-1 and Tn-caspase-1 transcribed by an RNA polymerase III promoter; the recombinant virus of the vector expresses double-strand small RNA in a host cell,the caspase-1 encoded by the silent host cell is interfered through the RNA, so that the apoptosis of the host cell is inhibited, and the expression level of a foreign protein is obviously improved.The broad-spectrum anti-apoptosis rhabdovirus expression vector can be used in the industrial production of protein preparations and vaccines.
Owner:陕西杆粒生物科技有限公司
Composition for treating contact dermatitis comprising pellitorine as an active ingredient
InactiveCN104434889AReduce skin thicknessInhibition of secretionCosmetic preparationsMake-upContact dermatitisDecomposition
The present invention relates to a composition including pellitorine as an active ingredient for alleviating contact dermatitis. A pellitorine compound which is an active ingredient of the composition according to the present invention is secreted in the early stage of various strong inflammatory diseases so as to control the secretion of IL-1beta which is cytokine promoting an inflammatory response and also control the proliferation of T cells and the secretion of IL-2, IL-4, or IFN-gamma which is cytokine secreted from T cells so that immunity can be regulated. Moreover, the compound exhibits activities in controlling the secretion of IL-1beta, inhibiting the decomposition cleavage of caspase-1, having no cytotoxicity, and decreasing skin thickness in contact dermatitis in an experiment using a contact dermatitis animal model as an animal model. Accordingly, it is expected that the composition of the present invention can be usefully used as a pharmaceutical composition, a cosmetic composition, or a functional food composition for preventing or treating inflammatory skin diseases like contact dermatitis.
Owner:CHUNG ANG UNIV IND ACADEMIC COOP FOUND +3
Ameliorative effects of a whole coffee fruit extract on age-related neurodegenerative disease
InactiveUS20190159474A1Reduce expressionReduce depositionNervous disorderRoasted coffee treatmentDiseaseChlorogenic acid
The invention provides a method of extracting whole coffee fruit, an extract obtained from the method, and method of ameliorating age-related neurodegenerative diseases using said extract. The whole coffee fruit extract may be extracted by water, methanol, ethanol, or acetone and may comprise chlorogenic acid (CA) and procyanidine. The expression levels of p-CREB, BDNF, p-eIF2α, BACE-1, Aβ, NLRP3, caspase-1, IL-1β and COX-2 which may relate to age-related neurodegenerative diseases can be modulated.
Owner:LYTONE ENTERPRISE INC
Method for treating inflammatory disorder
InactiveUS20150005390A1Inhibit expressionBiocideEther/acetal active ingredientsBiological activationSecretion
The present invention relates to a method for treating inflammatory disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of 2-methoxy-4-methylphenol or a pharmaceutically acceptable salt or a physiologically functional derivative thereof, wherein the compound is in a therapeutically effective amount to inhibit NO or IL-6 expression, caspase-1 activation or IL-1β secretion, and NLRP3 and IL-1β precursor expression in inflammatory cells of the subject.
Owner:NAT DEFENSE MEDICAL CENT
Lactic acid bacteria and their cellular components inducing immunoregulatory function, and method of obtaining the same
Owner:NAT INST OF AGROBIOLOGICAL SCI +1
Method and compositions for the identification of agents that have a potential effect against chronic inflammatory diseases
The present invention is based on two important experimental observations: The first observation is that increased extracellular concentrations of ionized calcium are found in erosive arthritis and stimulate monocytic IL-1β release via the CaSR and GPRC6A. Simultaneous stimulation of monocytes with calcium ions and selected TLR ligands results in a 20-fold increased IL1β response compared to lipopolysaccharide (LPS) alone. During the crosstalk between GPCR and TLR signaling, phospholipase C is activated, which triggers calcium dependent potassium channels, resulting in potassium efflux, caspase-1 activation and IL-1β release. The amplification of IL1β secretion at sites of locally increased calcium ion concentrations aggravates rheumatoid arthritis. The second important observation is that both CaSR and GPRC6A, are highly expressed in the synovial membrane of patients with rheumatoid arthritis, but expression of GPRC6A, but not of CaSR, is lower in patients with osteoarthritis (s. FIG. 1). The latter is generally not accompanied by inflammation. Thus, expression of GPRC6A appears to be upregulated in chronic inflammatory situations. Based on these experimental observations the invention provides a method and compositions for the identification of agents that have a potential effect against chronic inflammatory conditions, in particular erosive arthritis and atherosclerosis.
Owner:UNIV LEIPZIG
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
InactiveUS20120315649A1Eliminate needEasy to adaptDisease diagnosisBiological testingBCL2 ANTAGONISTCell adhesion
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more biomarkers selected from the group consisting of Tumor necrosis factor receptor superfamily member 10B, Cadherin-16, Caspase-9, Bcl2 antagonist of cell death, Caspase-1, Cadherin-1, Poly [ADP-ribose] polymerase 1, Cyclin-dependent kinase inhibitor 1, Cadherin-5, Myoglobin, Apolipoprotein A-II, Mucin-16, Carcinoembryonic antigen-related cell adhesion molecule 5, and Cellular tumor antigen p53 as diagnostic and prognostic biomarker assays in renal injuries.
Owner:ASTUTE MEDICAL
Caspase-1 inhibitor targeting liver and application thereof
ActiveCN102977215BInhibition of activationActivation facilitates terminationPeptide/protein ingredientsAntipyreticAmino acid compositionPolymer
Owner:ARMY MEDICAL UNIV
Lung cancer's biomarkers and their methods and diagnostic kit
ActiveUS20170067898A1Reduce developmentFacilitating lung tumorigenesisTetrapeptide ingredientsBiological material analysisCaspase-11Caspase 4
The present invention relates to the use as a biomarker of the active form of a human caspase protein, preferably the human caspase-4 or caspase-1, or of the active form of the protein encoded by an orthologue gene of the human caspase protein, preferably by an orthologue gene of the human caspase-4, for example the murine caspase-11 protein, in a method of diagnosis and / or prognosis and / or of monitoring the progression of a tumor, particularly lung cancer.
Owner:IMMUNEPHARMA
Application of NALP3-ASC inflammation complex and activator inhibitor thereof in terms of preparation of medicines for treating prion diseases
InactiveCN102641501BPromote activationNervous disorderMicrobiological testing/measurementDiseaseNALP3
The invention discloses application of an NALP3-ASC inflammation complex and an activator inhibitor thereof in terms of preparation of medicines for treating prion diseases. Experiments show that prion infects microgliacyte, NALP3-ASC inflammation complex enhanced caspase-1 and IL-1beta activation are formed. The inflammation complex NALP3 inhibitor can suppress NALP3 and ASC expression, and then suppresses activation and release of the caspase-1 and IL-1beta. The invention provides the application of the NALP3-ASC inflammation complex inhibitor for screening medicines for treating the prion diseases, by means of cell co-stimulation for a sample to be detected and the prion, total RNA (ribonucleic acid) of treated cells is extracted, NALP3 and ASC are detected by a qPCR (quantitative polymerase chain reaction) method, expression suppression conditions of the sample to mRNA (messenger ribonucleic acid) of the NALP3 and the ASC are judged according to PCR (polymerase chain reaction) amplification results, accordingly medicines for resisting Prion diseases are screened out, and effects of preventing, treating or controlling the prion diseases are realized.
Owner:CHINA AGRI UNIV
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
InactiveCN102792161BEasy to understandDisease diagnosisBiological testingCell adhesionBCL2 ANTAGONIST
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more biomarkers selected from the group consisting of Tumor necrosis factor receptor superfamily member 10B, Cadherin-16, Caspase-9, Bcl2 antagonist of cell death, Caspase-1, Cadherin-1, Poly [ADP-ribose] polymerase 1, Cyclin-dependent kinase inhibitor 1, Cadherin-5, Myoglobin, Apolipoprotein A-II, Mucin-16, Carcinoembryonic antigen-related cell adhesion molecule 5, and Cellular tumor antigen p53 as diagnostic and prognostic biomarker assays in renal injuries.
Owner:ASTUTE MEDICAL
Method for preparing antibody aiming at beet armyworm caspase-1
The invention relates to a method for preparing antibody aiming at beet armyworm caspase-1. The method comprises the following steps: immunizing an animal through polypeptide as shown in SEQ ID NO: 1 of an amino acid sequence, collecting serum of the animal, and purifying antibody from the serum. The invention further discloses the antibody obtained through the method. The invention further discloses a method for detecting beet armyworm caspase-1 large-subunit through the antibody. Through the adoption of the method and the antibody, the beet armyworm caspase-1 large-subunit in a sample can be specifically detected, and moreover, excitation of caspase-1 protein during insect cell apoptosis is initially detected, that is, breakage of large and small-subunit is detected. The method has important significance for the research on the toxicological meaning of the insect caspase gene family and the development of a new pesticide taking caspase as a target.
Owner:INST OF PLANT PROTECTION CHINESE ACAD OF AGRI SCI
Application of wedelolactone in preparing drug for treating keratomycosis
The invention belongs to the technical field of pharmacy, and discloses application of wedelolactone in preparing a drug for treating keratomycosis. The wedelolactone has a therapeutic effect on the keratomycosis in vivo and in vitro conditions. Under the in vitro conditions, the effect of the wedelolactone on IL-1beta secretion is studied by a human macrophage model stimulated by aspergillus fumigatus. Under the in vivo conditions, a C57BL / 6 mouse keratomycosis model is adopted to study the effect of wedelolactone on corneal clinical scores, pathological changes, Caspase-1 signaling pathway and interleukin-1beta secretion in model mice. Furthermore, the application of the wedelolactone in combination with natamycin in preparing the drug for treating the wedelolactone is further provided.
Owner:THE AFFILIATED HOSPITAL OF QINGDAO UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com